Abstract
Medical management of heart failure (HF) has evolved and has achieved significant survival benefits, resulting in highly complex medication regimens. Complex medication regimens create challenges for older adults, including nonadherence and increased adverse drug events, especially associated with cognitive impairment, physical limitations, or lack of social support. However, the association between medication complexity and patients’ health outcomes among older adults with HF is unclear. The purpose of this review is to address how the complexity of HF medications has been assessed in the literature and what clinical outcomes are associated with medication regimen complexity in HF. Further, we aimed to explore how older adults were represented in those studies. The Medication Regimen Complexity Index was the most commonly used tool for assessment of medication regimen complexity. Rehospitalization was most frequently assessed as the clinical outcome, and other studies used medication adherence, quality of life, healthcare utilization, healthcare cost, or side effect. However, the studies showed inconsistent results in the association between the medication regimen complexity and clinical outcomes. We also identified an extremely small number of studies that focused on older adults. Notably, current medication regimen complexity tools did not consider a complicated clinical condition of an older adult with multimorbidity, therapeutic competition, drug interactions, or altered tolerance to the usual dose strength of the medications. Furthermore, the outcomes that studies assessed were rarely comprehensive or patient centered. More studies are required to fill the knowledge gap identifying more comprehensive and accurate medication regimen complexity tools and more patient-centered outcome assessment.
Similar content being viewed by others
References
Voigt J, Sasha John M, Taylor A, Krucoff M, Reynolds MR, Michael GC. A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. Clin Cardiol. 2014;37:312–21.
Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–19.
Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014–2020). Pharmacoeconomics. 2020;38:1219–36.
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American heart association. Circulation. 2022;145:e153–639.
Rich MW. Management of heart failure in the elderly. Heart Fail Rev. 2002;7:89–97.
Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014;11:329–37.
Freidman, B. (AHRQ), Jiang, H.J. (AHRQ) and Russo, C.A. (Thomson Reuters). Medicare Hospital Stays: Comparisons between the Fee-for-Service Plan and Alternative Plans, 2006. HCUP Statistical Brief #66. 2009. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb66.pdf.
Minhas A, Mannan K, Ijaz SH, Jamal S, et al. Trends in characteristics and outcomes in primary heart failure hospitalizations among older population in the United States, 2004 to 2018. Circ Heart Fail. 2022;15:e008943.
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–1032.
Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A. Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Card Fail. 2011;17:217–23.
Volpe M, Chin D, Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol. 2010;24:9–17.
Marcum ZA, Amuan ME, Hanlon JT, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012;60:34–41.
Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124:136–43.
Wu J, Moser DK, Lennie TA, Burkhart PV. Medication adherence in patients who have heart failure: a review of the literature. Nurs Clin N Am. 2008;43:133–53.
Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226–33.
Page RL2, O'Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016; 134:e32-69.
Lazzarini V, Mentz RJ, Fiuzat M, Metra M, O’Connor CM. Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail. 2013;15:717–23.
Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med. 2005;165:2069–76.
Sauvé MJ, Lewis WR, Blankenbiller M, Rickabaugh B, Pressler SJ. Cognitive impairments in chronic heart failure: a case controlled study. J Card Fail. 2009;15:1–10.
Hawkins LA, Kilian S, Firek A, Kashner TM, Firek CJ, Silvet H. Cognitive impairment and medication adherence in outpatients with heart failure. Heart Lung. 2012;41:572–82.
Paquin AM, Zimmerman KM, Kostas TR, et al. Complexity perplexity: a systematic review to describe the measurement of medication regimen complexity. Expert Opin Drug Saf. 2013;12:829–40.
Mansur N, Weiss A, Beloosesky Y. Looking beyond polypharmacy: quantification of medication regimen complexity in the elderly. Am J Geriatr Pharmacother. 2012;10:223–9.
Willson MN, Greer CL, Weeks DL. Medication regimen complexity and hospital readmission for an adverse drug event. Ann Pharmacother. 2014;48:26–32.
George J, Phun YT, Bailey MJ, Kong DC, Stewart K. Development and validation of the medication regimen complexity index. Ann Pharmacother. 2004;38:1369–76.
Kelley S. Measurement of Complexity of Medication Regimens of the Elderly. 1988. University of Missouri, Columbia, Missouri. Master’s degree thesis/dissertation.
Conn VS, Taylor SG, Kelley S. Medication regimen complexity and adherence among older adults. Image J Nurs Sch. 1991;23:231–5.
Yam FK, Lew T, Eraly SA, Lin H, Hirsch JD, Devor M. Changes in medication regimen complexity and the risk for 90-day hospital readmission and/or emergency department visits in U.S .Veterans with heart failure. Res Soc Adm Pharm. 2016;12:713–21.
Abou-Karam N, Bradford C, Lor KB, Barnett M, Ha M, Rizos A. Medication regimen complexity and readmissions after hospitalization for heart failure, acute myocardial infarction, pneumonia, and chronic obstructive pulmonary disease. SAGE Open Med. 2016;4:2050312116632426.
Goldstein CM, Gathright EC, Gunstad J, et al. Depressive symptoms moderate the relationship between medication regimen complexity and objectively measured medication adherence in adults with heart failure. J Behav Med. 2017;40:602–11.
Wilkening GL, Brune S, Saenz PF, Vega LM, Kalich BA. Correlation between medication regimen complexity and quality of life in patients with heart failure. Res Social Adm Pharm. 2020;16:1498–501.
Libby AM, Fish DN, Hosokawa PW, et al. Patient-level medication regimen complexity across populations with chronic disease. Clin Ther. 2013;35:385-398.e1.
Vik SA, Hogan DB, Patten SB, Johnson JA, Romonko-Slack L, Maxwell CJ. Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs Aging. 2006;23:345–56.
Nieuwenhuis MMW, Jaarsma T, van Veldhuisen DJ, van der Wal MHL. Self-reported versus “true” adherence in heart failure patients: a study using the Medication Event Monitoring System. Neth Hear J. 2012;20:313–9.
Hauptman PJ, Pressler SJ, Sackner-Bernstein J, Ordronneau P, Udelson JE, Investigators C. Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure. Am J Cardiol. 2006;98:6066.
Cobretti MR, Page RL, Linnebur SA, et al. Medication regimen complexity in ambulatory older adults with heart failure. Clin Intervent Aging. 2017;12:679–86.
Wimmer BC, Bell JS, Fastbom J, Wiese MD, Johnell K. Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study. Ann Pharmacother. 2016;50:89–95.
Colavecchia AC, Putney DR, Johnson ML, Aparasu RR. Discharge medication complexity and 30-day heart failure readmissions. Res Social Adm Pharm. 2017;13:857–63.
Udelson JE, Pressler SJ, Sackner-Bernstein J, et al. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial. J Card Fail. 2009;15:385–93.
Peron EP, Gray SL, Hanlon JT. Medication Use and Functional Status Decline in Older Adults: A Narrative Review. Am J Geriatr Pharmacother. 2011;9:378–91.
Brysch EG, Cauthon KAB, Kalich BA, Sarbacker GB. Medication regimen complexity index in the elderly in an outpatient setting: a literature review. Consult Pharm. 2018;33:484–96.
Howell EH, Senapati A, Hsich E, Gorodeski EZ. Medication self-management skills and cognitive impairment in older adults hospitalized for heart failure: a cross-sectional study. SAGE Open Med. 2017;5:2050312117700301.
Fröhlich SE, Zaccolo AV, da Silva SL, Mengue SS. Association between drug prescribing and quality of life in primary care. Pharm World Sci. 2010;32:744–51.
Maddox TM, Januzzi JL, Allen LA, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;77:772–810.
American Geriatrics Society. Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;2019(67):674–94.
Saraf AA, Petersen AW, Simmons SF, et al. Medications associated with geriatric syndromes and their prevalence in older hospitalized adults discharged to skilled nursing facilities. J Hosp Med. 2016;11:694–700.
Brinker LM, Konerman MC, Navid P, et al. Complex and potentially harmful medication patterns in heart failure with preserved ejection fraction. Am J Med. 2021;134:374–82.
Lorgunpai SJ, Grammas M, Lee DS, McAvay G, Charpentier P, Tinetti ME. Potential therapeutic competition in community-living older adults in the US: use of medications that may adversely affect a coexisting condition. PLoS ONE. 2014;9: e89447.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr. Kwak receives funding from National Institute on Aging 1R24AG064025 and receives consult fee from the Endocrine & Diabetes Plus Clinic of Houston and Institute for Healthcare Improvement. Dr. Goyal is supported by American Heart Association grant 20CDA35310455, National Institute on Aging grant K76AG064428, and Loan Repayment Program award L30AG060521; Dr. Goyal receives personal fees for medicolegal consulting related to heart failure; and has received honoraria from Akcea inc. and Bionest inc. Dr. Hummel is the PI or co-I for studies funded by Pfizer, Novartis, Corvia and Axon, and has funding from National Institute on Aging, National Heart, Lung, and Blood Institute, and Veterans Affairs Clinical Science Research and Development. Dr. Hummel also had previously received research funding from PurFoods, LLC. Dr. Kim receives personal fees from Alosa Health and research funding from the National Institute of Health for projects unrelated to the current work. Dr. Holly Holmes received research funding from Healthcare Services Corporation, which is a foundation of Blue Cross Blue Shield, for a study of deprescribing. The funding is unrelated to the manuscript under consideration. Dr. Dhoble is a consultant and proctor for Abbott Vascular. Dr. Aparasu receives research funding from Astellas Inc., Incyte Corp., Gilead, and Novartis Inc. for projects unrelated to the current work.
Funding
This work was supported by the National Institutes on Aging R24AG064025. The funding agency did not have any involvement in study design, data collection, analysis, or interpretation of the data, writing of the manuscript or decision to submit the article for publication.
Author contribution
MJK: conceptualization, data curation, investigation, resources, writing—original draft; MC: data curation, investigation, resources; PG and SH: conceptualization, validation, supervision, writing—review and editing; AD, AD and DHK: validation, supervision, writing—review and editing; RA and HH: conceptualization, supervision, writing—review and editing.
Availability of data and materials
Not applicable.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Code availability
Not applicable.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kwak, M., Cheng, M., Goyal, P. et al. Medication Complexity Among Older Adults with HF: How Can We Assess Better?. Drugs Aging 39, 851–861 (2022). https://doi.org/10.1007/s40266-022-00979-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40266-022-00979-2